Regeneron Wins Expanded Eylea Approval for CRVO

The FDA Friday approved a second indication for Regeneron Pharmaceuticals’ Eylea to treat macular edema following central retinal vein occlusion (CRVO). The approval was based on two late-stage trials that showed Eylea (aflibercept) significantly improved visual outcomes, Regeneron said.
Drug Industry Daily